MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

0.97 -2.02

Buy Sell

Overview

Share price change

24h

Current

Min

0.96

Max

0.98

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+400% upside

Market Stats
By TradingEconomics
Market Cap	-11M 115M
Previous open	2.99
Previous close	0.97

News Sentiment

By Acuity

50%

151 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 gru 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

WiseTech to Sell Expedient to Appease Competition Regulator

30 gru 2025, 17:12 UTC

Major Market Movers

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 gru 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30 gru 2025, 21:08 UTC

Market Talk

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30 gru 2025, 20:41 UTC

Market Talk

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30 gru 2025, 20:37 UTC

Earnings

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30 gru 2025, 19:29 UTC

Market Talk

Corn Extends Pullback in Light Trade -- Market Talk

30 gru 2025, 18:29 UTC

Market Talk

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 gru 2025, 16:20 UTC

Earnings

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30 gru 2025, 16:10 UTC

Market Talk

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30 gru 2025, 15:24 UTC

Market Talk

Australian Dollar Could Rise Versus Sterling -- Market Talk

30 gru 2025, 15:10 UTC

Acquisitions, Mergers, Takeovers

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30 gru 2025, 14:24 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30 gru 2025, 14:22 UTC

Acquisitions, Mergers, Takeovers

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30 gru 2025, 14:20 UTC

Acquisitions, Mergers, Takeovers

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30 gru 2025, 14:17 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30 gru 2025, 14:16 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30 gru 2025, 14:14 UTC

Acquisitions, Mergers, Takeovers

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30 gru 2025, 14:12 UTC

Acquisitions, Mergers, Takeovers

LVMH: Les Editions Croque Futur Is a French Publishing House

30 gru 2025, 14:10 UTC

Acquisitions, Mergers, Takeovers

LVMH Acquires Les Editions Croque Futur

30 gru 2025, 13:49 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30 gru 2025, 13:36 UTC

Market Talk

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30 gru 2025, 13:30 UTC

Market Talk

Crude Futures Gain in Light Holiday Trade -- Market Talk

30 gru 2025, 12:55 UTC

Market Talk

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30 gru 2025, 11:55 UTC

Market Talk

Earnings

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30 gru 2025, 11:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30 gru 2025, 11:35 UTC

Acquisitions, Mergers, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

400% upside

12 Months Forecast

Average 5 USD 400%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

151 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.